Diabetic nephropathy: Traditional to proteomic markers

Clinica Chimica Acta

Volumn 421, Issue , 2013, Pages 17-30

  Moresco, Rafael N ^a   Sangoi, Manuela B ^a   De Carvalho, José A M ^a   Tatsch, Etiane ^a   Bochi, Guilherme V ^a  

^a FEDERAL UNIVERSITY OF SANTA MARIA   (Brazil)

Author keywords

Biomarkers; Diabetic nephropathy; Inflammation; Oxidative stress; Proteomics

Indexed keywords

8 HYDROXYDEOXYGUANOSINE; ALBUMIN; ALKALINE PHOSPHATASE; ALPHA 1 MICROGLOBULIN; BETA 2 MICROGLOBULIN; BIOLOGICAL MARKER; CD40 LIGAND; COLLAGEN TYPE 4; FATTY ACID BINDING PROTEIN; GAMMA GLUTAMYLTRANSFERASE; INTERLEUKIN 6; KIDNEY INJURY MOLECULE 1; LIVER TYPE FATTY ACID BINDING PROTEIN; MONOCYTE CHEMOTACTIC PROTEIN 1; N ACETYL BETA GLUCOSAMINIDASE; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; NITRIC OXIDE; PENTOSIDINE; RETINOL BINDING PROTEIN; TRANSFERRIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ALBUMINURIA; DIABETIC NEPHROPATHY; DISEASE COURSE; HUMAN; INFLAMMATION; KIDNEY DYSFUNCTION; KIDNEY INJURY; MONITORING; OXIDATIVE STRESS; PATHOGENESIS; PREDICTION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEOMICS; REVIEW;

ACETYLGLUCOSAMINIDASE; ALBUMINURIA; BIOLOGICAL MARKERS; DEOXYGUANOSINE; DIABETIC NEPHROPATHIES; DISEASE PROGRESSION; EARLY DIAGNOSIS; HUMANS; INFLAMMATION; KIDNEY; MEMBRANE GLYCOPROTEINS; NEOPLASM PROTEINS; OXIDATIVE STRESS; PROGNOSIS; PROTEOMICS; RECEPTORS, VIRUS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84875598343     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2013.02.019     Document Type: Review

References (256)

1. Gross J.L., de Azevedo M.J., Silveiro S.P., Canani L.H., Caramori M.L., Zelmanovitz T. Diabetic nephropathy: diagnosis, prevention, and treatment. Diabetes Care 2005, 28:164-176.
2. Felehgari V., Rahimi Z., Mozafari H., Vaisi-Raygani A. ACE gene polymorphism and serum ACE activity in Iranians type II diabetic patients with macroalbuminuria. Mol Cell Biochem 2011, 346:23-30.
3. Molitch M.E., DeFronzo R.A., Franz M.J., et al. Nephropathy in diabetes. Diabetes Care 2004, 27(Suppl. 1):S79-S83.
4. Wada J., Makino H. Historical chronology of basic and clinical research in diabetic nephropathy and contributions of Japanese scientists. Clin Exp Nephrol 2009, 13:405-414.
5. Abdel-Rahman E.M., Saadulla L., Reeves W.B., Awad A.S. Therapeutic modalities in diabetic nephropathy: standard and emerging approaches. J Gen Intern Med 2012, 27:458-468.
6. Ziyadeh F.N. Mediators of diabetic renal disease: the case for tgf-Beta as the major mediator. J Am Soc Nephrol 2004, 15(Suppl. 1):S55-S57.
7. Jerums G., Premaratne E., Panagiotopoulos S., Clarke S., Power D.A., MacIsaac R.J. New and old markers of progression of diabetic nephropathy. Diabetes Res Clin Pract 2008, 82(Suppl. 1):S30-S37.
8. Dronavalli S., Duka I., Bakris G.L. The pathogenesis of diabetic nephropathy. Nat Clin Pract Endocrinol Metab 2008, 4:444-452.
9. Steinke J.M., Sinaiko A.R., Kramer M.S., et al. The early natural history of nephropathy in Type 1 diabetes: III. Predictors of 5-year urinary albumin excretion rate patterns in initially normoalbuminuric patients. Diabetes 2005, 54:2164-2171.
10. Matheson A., Willcox M.D., Flanagan J., Walsh B.J. Urinary biomarkers involved in type 2 diabetes: a review. Diabetes Metab Res Rev 2010, 26:150-171.
11. Brenner B.M., Hostetter T.H., Humes H.D. Glomerular permselectivity: barrier function based on discrimination of molecular size and charge. Am J Physiol 1978, 234:F455-F460.
12. Brenner B.M., Hostetter T.H., Humes H.D. Molecular basis of proteinuria of glomerular origin. N Engl J Med 1978, 298:826-833.
13. Varghese S.A., Powell T.B., Budisavljevic M.N., et al. Urine biomarkers predict the cause of glomerular disease. J Am Soc Nephrol 2007, 18:913-922.
14. Najafian B., Mauer M. Progression of diabetic nephropathy in type 1 diabetic patients. Diabetes Res Clin Pract 2009, 83:1-8.
15. Ziyadeh F.N. Significance of tubulointerstitial changes in diabetic renal disease. Kidney Int 1996, 54:S10-S13. [Suppl.].
16. Suzuki D., Miyazaki M., Jinde K., et al. In situ hybridization studies of matrix metalloproteinase-3, tissue inhibitor of metalloproteinase-1 and type IV collagen in diabetic nephropathy. Kidney Int 1997, 52:111-119.
17. Birn H., Christensen E.I. Renal albumin absorption in physiology and pathology. Kidney Int 2006, 69:440-449.
18. Ruggenenti P., Remuzzi G. Time to abandon microalbuminuria?. Kidney Int 2006, 70:1214-1222.
19. de Jong P.E., Gansevoort R.T. Albuminuria in non-primary renal disease: risk marker rather than risk factor. Nephrol Dial Transplant 2010, 25:656-658.
20. American Diabetes A Standards of medical care in diabetes-2008. Diabetes Care 2008, 31(Suppl. 1):S12-S54.
21. Adler A.I., Stevens R.J., Manley S.E., et al. Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int 2003, 63:225-232.
22. de Zeeuw D., Remuzzi G., Parving H.H., et al. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. Kidney Int 2004, 65:2309-2320.
23. Afghahi H., Cederholm J., Eliasson B., et al. Risk factors for the development of albuminuria and renal impairment in type 2 diabetes-the Swedish National Diabetes Register (NDR). Nephrol Dial Transplant 2011, 26:1236-1243.
24. Mogensen C.E. Microalbuminuria as a predictor of clinical diabetic nephropathy. Kidney Int 1987, 31:673-689.
25. Perkins B.A., Ficociello L.H., Roshan B., Warram J.H., Krolewski A.S. In patients with type 1 diabetes and new-onset microalbuminuria the development of advanced chronic kidney disease may not require progression to proteinuria. Kidney Int 2010, 77:57-64.
26. Bruno G., Merletti F., Bargero G., et al. Estimated glomerular filtration rate, albuminuria and mortality in type 2 diabetes: the Casale Monferrato study. Diabetologia 2007, 50:941-948.
27. Yokoyama H., Araki S., Haneda M., et al. Chronic kidney disease categories and renal-cardiovascular outcomes in type 2 diabetes without prevalent cardiovascular disease: a prospective cohort study (JDDM25). Diabetologia 2012, 55:1911-1918.
28. Ninomiya T., Perkovic V., de Galan B.E., et al. Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes. J Am Soc Nephrol 2009, 20:1813-1821.
29. Mogensen C.E., Christensen C.K. Predicting diabetic nephropathy in insulin-dependent patients. N Engl J Med 1984, 311:89-93.
30. Ito H., Takeuchi Y., Ishida H., et al. High frequencies of diabetic micro- and macroangiopathies in patients with type 2 diabetes mellitus with decreased estimated glomerular filtration rate and normoalbuminuria. Nephrol Dial Transplant 2010, 25:1161-1167.
31. Dwyer J.P., Parving H.H., Hunsicker L.G., Ravid M., Remuzzi G., Lewis J.B. Renal dysfunction in the presence of normoalbuminuria in type 2 diabetes: results from the DEMAND study. Cardiorenal Med 2012, 2:1-10.
32. Iijima T., Suzuki S., Sekizuka K., et al. Follow-up study on urinary type IV collagen in patients with early stage diabetic nephropathy. J Clin Lab Anal 1998, 12:378-382.
33. Narita T., Hosoba M., Kakei M., Ito S. Increased urinary excretions of immunoglobulin g, ceruloplasmin, and transferrin predict development of microalbuminuria in patients with type 2 diabetes. Diabetes Care 2006, 29:142-144.
34. Yagame M., Kim Y., Zhu D., et al. Differential distribution of type IV collagen chains in patients with diabetic nephropathy in non-insulin-dependent diabetes mellitus. Nephron 1995, 70:42-48.
35. Zeisberg M., Bonner G., Maeshima Y., et al. Renal fibrosis: collagen composition and assembly regulates epithelial-mesenchymal transdifferentiation. Am J Pathol 2001, 159:1313-1321.
36. Takizawa H., Satoh T., Kurusu A., et al. Increase of urinary type IV collagen in normoalbuminuric patients with impaired glucose tolerance. Nephron 1998, 79:474-475.
37. Banu N., Hara H., Okamura M., Egusa G., Yamakido M. Urinary excretion of type IV collagen and laminin in the evaluation of nephropathy in NIDDM: comparison with urinary albumin and markers of tubular dysfunction and/or damage. Diabetes Res Clin Pract 1995, 29:57-67.
38. Kado S., Aoki A., Wada S., et al. Urinary type IV collagen as a marker for early diabetic nephropathy. Diabetes Res Clin Pract 1996, 31:103-108.
39. Kotajima N., Kimura T., Kanda T., et al. Type IV collagen as an early marker for diabetic nephropathy in non-insulin-dependent diabetes mellitus. J Diabetes Complications 2000, 14:13-17.
40. Watanabe H., Sanada H., Shigetomi S., Katoh T., Watanabe T. Urinary excretion of type IV collagen as a specific indicator of the progression of diabetic nephropathy. Nephron 2000, 86:27-35.
41. Cohen M.P., Lautenslager G.T., Shearman C.W. Increased collagen IV excretion in diabetes. A marker of compromised filtration function. Diabetes Care 2001, 24:914-918.
42. Tomino Y., Suzuki S., Azushima C., et al. Asian multicenter trials on urinary type IV collagen in patients with diabetic nephropathy. J Clin Lab Anal 2001, 15:188-192.
43. Okonogi H., Nishimura M., Utsunomiya Y., et al. Urinary type IV collagen excretion reflects renal morphological alterations and type IV collagen expression in patients with type 2 diabetes mellitus. Clin Nephrol 2001, 55:357-364.
44. Katavetin P., Katavetin P., Susantitaphong P., et al. Urinary type IV collagen excretion predicts subsequent declining renal function in type 2 diabetic patients with proteinuria. Diabetes Res Clin Pract 2010, 89:33-35.
45. Araki S., Haneda M., Koya D., et al. Association between urinary type IV collagen level and deterioration of renal function in type 2 diabetic patients without overt proteinuria. Diabetes Care 2010, 33:1805-1810.
46. Morita M., Uchigata Y., Hanai K., Ogawa Y., Iwamoto Y. Association of urinary type IV collagen with GFR decline in young patients with type 1 diabetes. Am J Kidney Dis 2011, 58:915-920.
47. Cohen-Bucay A., Viswanathan G. Urinary markers of glomerular injury in diabetic nephropathy. Int J Nephrol 2012, 10.1155/2012/146987.
48. Hong C.Y., Chia K.S. Markers of diabetic nephropathy. J Diabetes Complications 1998, 12:43-60.
49. McCormick C.P., Konen J.C., Shihabi Z.K. Microtransferrinuria and microalbuminuria. I. In the diabetic human. Clin Physiol Biochem 1990, 8:53-58.
50. O'Donnell M.J., Martin P., Florkowski C.M., et al. Urinary transferrin excretion in type 1 (insulin-dependent) diabetes mellitus. Diabet Med 1991, 8:657-661.
51. Kazumi T., Hozumi T., Ishida Y., et al. Increased urinary transferrin excretion predicts microalbuminuria in patients with type 2 diabetes. Diabetes Care 1999, 22:1176-1180.
52. Worthley D.L., Harvey N.T., Hill N.L., Walsh R.L., Edwards J.B., Roberts A.P. Urinary transferrin and albumin concentrations in patients with type 1 diabetes and normal controls: the search for the first protein lost. Clin Biochem 2001, 34:83-85.
53. Narita T., Sasaki H., Hosoba M., et al. Parallel increase in urinary excretion rates of immunoglobulin G, ceruloplasmin, transferrin, and orosomucoid in normoalbuminuric type 2 diabetic patients. Diabetes Care 2004, 27:1176-1181.
54. Telci A., Cakatay U., Kayali R., et al. Oxidative protein damage in plasma of type 2 diabetic patients. Horm Metab Res 2000, 32:40-43.
55. Hellemons M.E., Kerschbaum J., Bakker S.J., et al. Validity of biomarkers predicting onset or progression of nephropathy in patients with type 2 diabetes: a systematic review. Diabet Med 2012, 29:567-577.
56. Memisogullari R., Bakan E. Levels of ceruloplasmin, transferrin, and lipid peroxidation in the serum of patients with type 2 diabetes mellitus. J Diabetes Complications 2004, 18:193-197.
57. Flynn F.V. Assessment of renal function: selected developments. Clin Biochem 1990, 23:49-54.
58. Barratt J., Topham P. Urine proteomics: the present and future of measuring urinary protein components in disease. Can Med Assoc J 2007, 177:361-368.
59. D'Amico G., Bazzi C. Urinary protein and enzyme excretion as markers of tubular damage. Curr Opin Nephrol Hypertens 2003, 12:639-643.
60. Basturk T., Altuntas Y., Kurklu A., Aydin L., Eren N., Unsal A. Urinary N-acetyl B glucosaminidase as an earlier marker of diabetic nephropathy and influence of low-dose perindopril/indapamide combination. Ren Fail 2006, 28:125-128.
61. Tejler L., Grubb A.O. A complex-forming glycoprotein heterogeneous in charge and present in human plasma, urine, and cerebrospinal fluid. Biochim Biophys Acta 1976, 439:82-94.
62. Ekstrom B., Peterson P.A., Berggard I. A urinary and plasma alpha1-glycoprotein of low molecular weight: isolation and some properties. Biochem Biophys Res Commun 1975, 65:1427-1433.
63. Martin P., Hampton K.K., Walton C., Tindall H., Davies J.A. Microproteinuria in type 2 diabetes mellitus from diagnosis. Diabet Med 1990, 7:315-318.
64. O'Donnell M.J., Watson J., Martin P., Chapman C., Barnett A.H. Transferrinuria in type 2 diabetes: the effect of glycaemic control. Ann Clin Biochem 1991, 28:174-178.
65. Pfleiderer S., Zimmerhackl L.B., Kinne R., Manz F., Schuler G., Brandis M. Renal proximal and distal tubular function is attenuated in diabetes mellitus type 1 as determined by the renal excretion of alpha 1-microglobulin and Tamm-Horsfall protein. Clin Investig 1993, 71:972-977.
66. Brocco E., Fioretto P., Mauer M., et al. Renal structure and function in non-insulin dependent diabetic patients with microalbuminuria. Kidney Int 1997, 63:S40-S44. [Suppl.].
67. Walton C., Bodansky H.J., Wales J.K., Forbes M.A., Cooper E.H. Tubular dysfunction and microalbuminuria in insulin dependent diabetes. Arch Dis Child 1988, 63:244-249.
68. Marczewski K.T., Dziemidok P., Grzywna R., Krawczyk W. Microalbuminuria or micro-alpha-1-microglobulinuria: which one is better predictor of the development of the secondary nephropathy?. Clin Nephrol 1996, 45:136-137.
69. Hong C.Y., Hughes K., Chia K.S., Ng V., Ling S.L. Urinary alpha1-microglobulin as a marker of nephropathy in type 2 diabetic Asian subjects in Singapore. Diabetes Care 2003, 26:338-342.
70. Penders J., Delanghe J.R. Alpha 1-microglobulin: clinical laboratory aspects and applications. Clin Chim Acta 2004, 346:107-118.
71. Orlando R.A., Rader K., Authier F., et al. Megalin is an endocytic receptor for insulin. J Am Soc Nephrol 1998, 9:1759-1766.
72. Lonnemann G., Koch K.M. Beta(2)-microglobulin amyloidosis: effects of ultrapure dialysate and type of dialyzer membrane. J Am Soc Nephrol 2002, 13(Suppl. 1):S72-S77.
73. Grillenberger A., Weninger M., Lubec G. Determination of urinary low molecular weight proteins for the diagnosis of tubular damage. Padiatr Padol 1987, 22:229-234.
74. Piscator M. Early detection of tubular dysfunction. Kidney Int 1991, 34(Suppl. 1):S15-S17.
75. Sharifiaghdas F., Kashi A.H., Eshratkhah R. Evaluating percutaneous nephrolithotomy-induced kidney damage by measuring urinary concentrations of beta2-microglobulin. J Urol 2011, 8:277-282.
76. Hong C.Y., Chia K.S., Ling S.L. Urinary protein excretion in Type 2 diabetes with complications. J Diabetes Complications 2000, 14:259-265.
77. Yoshikawa R., Wada J., Seiki K., et al. Urinary PGDS levels are associated with vascular injury in type 2 diabetes patients. Diabetes Res Clin Pract 2007, 76:358-367.
78. Groop L., Makipernaa A., Stenman S., DeFronzo R.A., Teppo A.M. Urinary excretion of kappa light chains in patients with diabetes mellitus. Kidney Int 1990, 37:1120-1125.
79. Mocan Z., Erem C., Yildirim M., Telatar M., Deger O. Urinary beta 2-microglobulin levels and urinary N-acetyl-beta-d-glucosaminidase enzyme activities in early diagnosis of non-insulin-dependent diabetes mellitus nephropathy. Diabetes Res 1994, 26:101-107.
80. Kalansooriya A., Holbrook I., Jennings P., Whiting P.H. Serum cystatin C, enzymuria, tubular proteinuria and early renal insult in type 2 diabetes. Br J Biomed Sci 2007, 64:121-123.
81. Hosojima H., Miyauchi E., Morimoto S. Urinary excretion of angiotensin-converting enzyme in NIDDM patients with nephropathy. Diabetes Care 1989, 12:580-582.
82. Helaly M.A., Sheashaa H.A., Hatata el S.Z., Youssef A.B., Hegazi A., Abdel-Aal I.A. Endothelial dysfunction in geriatric diabetic patients: the role of microalbuminuria in elderly type 2 diabetic patients? A randomized controlled study. Int Urol Nephrol 2007, 39:333-338.
83. Soprano D.R., Soprano K.J., Goodman D.S. Retinol-binding protein messenger RNA levels in the liver and in extrahepatic tissues of the rat. J Lipid Res 1986, 27:166-171.
84. Lisowska-Myjak B. Serum and urinary biomarkers of acute kidney injury. Blood Purif 2010, 29:357-365.
85. Salem M.A., el-Habashy S.A., Saeid O.M., el-Tawil M.M., Tawfik P.H. Urinary excretion of n-acetyl-beta-d-glucosaminidase and retinol binding protein as alternative indicators of nephropathy in patients with type 1 diabetes mellitus. Pediatr Diabetes 2002, 3:37-41.
86. Dillon S.C., Taylor G.M., Shah V. Diagnostic value of urinary retinol-binding protein in childhood nephrotic syndrome. Pediatr Nephrol 1998, 12:643-647.
87. Bazzi C., Petrini C., Rizza V., et al. Urinary N-acetyl-beta-glucosaminidase excretion is a marker of tubular cell dysfunction and a predictor of outcome in primary glomerulonephritis. Nephrol Dial Transplant 2002, 17:1890-1896.
88. Liangos O., Perianayagam M.C., Vaidya V.S., et al. Urinary N-acetyl-beta-(d)-glucosaminidase activity and kidney injury molecule-1 level are associated with adverse outcomes in acute renal failure. J Am Soc Nephrol 2007, 18:904-912.
89. Vaidya V.S., Waikar S.S., Ferguson M.A., et al. Urinary biomarkers for sensitive and specific detection of acute kidney injury in humans. Clin Transl Sci 2008, 1:200-208.
90. Bernard A.M., Vyskocil A.A., Mahieu P., Lauwerys R.R. Assessment of urinary retinol-binding protein as an index of proximal tubular injury. Clin Chem 1987, 33:775-779.
91. Price R.G. The role of NAG (N-acetyl-beta-d-glucosaminidase) in the diagnosis of kidney disease including the monitoring of nephrotoxicity. Clin Nephrol 1992, 38(Suppl. 1):S14-S19.
92. Guder W.G., Hofmann W. Markers for the diagnosis and monitoring of renal tubular lesions. Clin Nephrol 1992, 38(Suppl. 1):S3-S7.
93. Watts G.F., Vlitos M.A., Morris R.W., Price R.G. Urinary N-acetyl-beta-d-glucosaminidase excretion in insulin-dependent diabetes mellitus: relation to microalbuminuria, retinopathy and glycaemic control. Diabete Metab 1988, 14:653-658.
94. Cheung C.K., Yeung V.T., Cockram C.S., Swaminathan R. Urinary excretion of albumin and enzymes in non-insulin-dependent Chinese diabetics. Clin Nephrol 1990, 34:125-130.
95. Lapsley M., Flynn F.V., Sansom P.A. Beta 2-glycoprotein-1 (apolipoprotein H) excretion and renal tubular malfunction in diabetic patients without clinical proteinuria. J Clin Pathol 1993, 46:465-469.
96. Uslu S., Efe B., Alatas O., et al. Serum cystatin C and urinary enzymes as screening markers of renal dysfunction in diabetic patients. J Nephrol 2005, 18:559-567.
97. Piwowar A., Knapik-Kordecka M., Fus I., Warwas M. Urinary activities of cathepsin B, N-acetyl-beta-d-glucosaminidase, and albuminuria in patients with type 2 diabetes mellitus. Med Sci Monit 2006, 12:CR210-CR214.
98. Kern E.F., Erhard P., Sun W., Genuth S., Weiss M.F. Early urinary markers of diabetic kidney disease: a nested case-control study from the Diabetes Control and Complications Trial (DCCT). Am J Kidney Dis 2010, 55:824-834.
99. Vaidya V.S., Niewczas M.A., Ficociello L.H., et al. Regression of microalbuminuria in type 1 diabetes is associated with lower levels of urinary tubular injury biomarkers, kidney injury molecule-1, and N-acetyl-beta-d-glucosaminidase. Kidney Int 2011, 79:464-470.
100. Kordonouri O., Hartmann R., Muller C., Danne T., Weber B. Predictive value of tubular markers for the development of microalbuminuria in adolescents with diabetes. Horm Res 1998, 50(Suppl. 1):23-27.
101. Hsiao P.H., Tsai W.S., Tsai W.Y., Lee J.S., Tsau Y.K., Chen C.H. Urinary N-acetyl-beta-d-glucosaminidase activity in children with insulin-dependent diabetes mellitus. Am J Nephrol 1996, 16:300-303.
102. Yamanouchi T., Kawasaki T., Yoshimura T., et al. Relationship between serum 1,5-anhydroglucitol and urinary excretion of N-acetylglucosaminidase and albumin determined at onset of NIDDM with 3-year follow-up. Diabetes Care 1998, 21:619-624.
103. Flandrois C., Gravagna B., Maire I., Mathieu M. Enzymuria. Ann Biol Clin 1986, 44:486-490.
104. Aragon G., Younossi Z.M. When and how to evaluate mildly elevated liver enzymes in apparently healthy patients. Cleve Clin J Med 2010, 77:195-204.
105. Jung K., Pergande M., Schimke E., Ratzmann K.P., Ilius A. Urinary enzymes and low-molecular-mass proteins as indicators of diabetic nephropathy. Clin Chem 1988, 34:544-547.
106. Morita E., Kaizu K., Uriu K., Hashimoto O., Komine N., Eto S. Clinical significance of urinary enzymes in diabetic nephropathy. J Diabet Complications 1991, 5:158-159.
107. De Carvalho J.A., Piva S.J., Hausen B.S., et al. Assessment of urinary gamma-glutamyltransferase and alkaline phosphatase for diagnosis of diabetic nephropathy. Clin Chim Acta 2011, 412:1407-1411.
108. Zhang H.F., Ong W.Y., Leong S.K., Laperche Y. Species differences in the localisation of gamma-glutamyl transpeptidase immunopositive cells at the blood-brain interface. J Hirnforsch 1997, 38:323-330.
109. Panchenko E.L., Chesney R.W., Roy S., Budreau A.M., Boehm K.A. The differential diagnostic value of urinary enzyme and amino acid excretion in children with nephrotic syndrome. Pediatr Nephrol 1994, 8:142-147.
110. Kwon O., Molitoris B.A., Pescovitz M., Kelly K.J. Urinary actin, interleukin-6, and interleukin-8 may predict sustained ARF after ischemic injury in renal allografts. Am J Kidney Dis 2003, 41:1074-1087.
111. Westhuyzen J., Endre Z.H., Reece G., Reith D.M., Saltissi D., Morgan T.J. Measurement of tubular enzymuria facilitates early detection of acute renal impairment in the intensive care unit. Nephrol Dial Transplant 2003, 18:543-551.
112. Jung K., Burchardt U. Urinary enzymes in research and in clinical medicine. Report on a symposium of the Humboldt-Universitat Berlin and the Bezirkskrankenhaus Frankfurt/Oder in Frankfurt/Oder, 22-25 April 1987. J Clin Chem Clin Biochem 1987, 25:823-828.
113. Ikenaga H., Suzuki H., Ishii N., Itoh H., Saruta T. Enzymuria in non-insulin-dependent diabetic patients: signs of tubular cell dysfunction. Clin Sci 1993, 84:469-475.
114. De Carvalho J.A., Bochi G.V., Sangoi M.B., Moresco R.N. Assessment of urinary gamma-glutamyltransferase in type 2 diabetic patients with glomerular hyperfiltration. Clin Chim Acta 2012, 413:817-818.
115. Mogensen C.E. Twelve shifting paradigms in diabetic renal disease and hypertension. Diabetes Res Clin Pract 2008, 82(Suppl. 1):S2-S9.
116. Portilla D., Dent C., Sugaya T., et al. Liver fatty acid-binding protein as a biomarker of acute kidney injury after cardiac surgery. Kidney Int 2008, 73:465-472.
117. Kamijo A., Sugaya T., Hikawa A., et al. Urinary excretion of fatty acid-binding protein reflects stress overload on the proximal tubules. Am J Pathol 2004, 165:1243-1255.
118. Nielsen S.E., Sugaya T., Tarnow L., et al. Tubular and glomerular injury in diabetes and the impact of ACE inhibition. Diabetes Care 2009, 32:1684-1688.
119. von Eynatten M., Baumann M., Heemann U., et al. Urinary L-FABP and anaemia: distinct roles of urinary markers in type 2 diabetes. Eur J Clin Invest 2010, 40:95-102.
120. Bolignano D., Donato V., Coppolino G., et al. Neutrophil gelatinase-associated lipocalin (NGAL) as a marker of kidney damage. Am J Kidney Dis 2008, 52:595-605.
121. Ricci Z., Ronco C. Today's approach to the critically ill patient with acute kidney injury. Blood Purif 2009, 27:127-134.
122. Mishra J., Ma Q., Kelly C., et al. Kidney NGAL is a novel early marker of acute injury following transplantation. Pediatr Nephrol 2006, 21:856-863.
123. Mitsnefes M.M., Kathman T.S., Mishra J., et al. Serum neutrophil gelatinase-associated lipocalin as a marker of renal function in children with chronic kidney disease. Pediatr Nephrol 2007, 22:101-108.
124. Nielsen S.E., Schjoedt K.J., Astrup A.S., et al. Neutrophil Gelatinase-Associated Lipocalin (NGAL) and Kidney Injury Molecule 1 (KIM1) in patients with diabetic nephropathy: a cross-sectional study and the effects of lisinopril. Diabet Med 2010, 27:1144-1150.
125. Nielsen S.E., Reinhard H., Zdunek D., et al. Tubular markers are associated with decline in kidney function in proteinuric type 2 diabetic patients. Diabetes Res Clin Pract 2012, 97:71-76.
126. Fu W.J., Xiong S.L., Fang Y.G., et al. Urinary tubular biomarkers in short-term type 2 diabetes mellitus patients: a cross-sectional study. Endocrine 2012, 41:82-88.
127. Ichimura T., Bonventre J.V., Bailly V., et al. Kidney injury molecule-1 (KIM-1), a putative epithelial cell adhesion molecule containing a novel immunoglobulin domain, is up-regulated in renal cells after injury. J Biol Chem 1998, 273:4135-4142.
128. Han W.K., Bailly V., Abichandani R., Thadhani R., Bonventre J.V. Kidney Injury Molecule-1 (KIM-1): a novel biomarker for human renal proximal tubule injury. Kidney Int 2002, 62:237-244.
129. van Timmeren M.M., van den Heuvel M.C., Bailly V., Bakker S.J., van Goor H., Stegeman C.A. Tubular kidney injury molecule-1 (KIM-1) in human renal disease. J Pathol 2007, 212:209-217.
130. Bangstad H.J., Seljeflot I., Berg T.J., Hanssen K.F. Renal tubulointerstitial expansion is associated with endothelial dysfunction and inflammation in type 1 diabetes. Scand J Clin Lab Invest 2009, 69:138-144.
131. Vaidya V.S., Ferguson M.A., Bonventre J.V. Biomarkers of acute kidney injury. Annu Rev Pharmacol Toxicol 2008, 48:463-493.
132. Vaidya V.S., Ozer J.S., Dieterle F., et al. Kidney injury molecule-1 outperforms traditional biomarkers of kidney injury in preclinical biomarker qualification studies. Nat Biotechnol 2010, 28:478-485.
133. Nielsen S.E., Andersen S., Zdunek D., Hess G., Parving H.H., Rossing P. Tubular markers do not predict the decline in glomerular filtration rate in type 1 diabetic patients with overt nephropathy. Kidney Int 2011, 79:1113-1118.
134. American Diabetes A Diagnosis and classification of diabetes mellitus. Diabetes Care 2010, 33(Suppl. 1):S62-S69.
135. Lebeche D., Davidoff A.J., Hajjar R.J. Interplay between impaired calcium regulation and insulin signaling abnormalities in diabetic cardiomyopathy. Nat Clin Pract Cardiovasc Med 2008, 5:715-724.
136. Pu L.J., Lu L., Xu X.W., et al. Value of serum glycated albumin and high-sensitivity C-reactive protein levels in the prediction of presence of coronary artery disease in patients with type 2 diabetes. Cardiovasc Diabetol 2006, 5:27.
137. Marfella R., D'Amico M., Di Filippo C., et al. Myocardial infarction in diabetic rats: role of hyperglycaemia on infarct size and early expression of hypoxia-inducible factor 1. Diabetologia 2002, 45:1172-1181.
138. Evans J.L., Goldfine I.D., Maddux B.A., Grodsky G.M. Oxidative stress and stress-activated signaling pathways: a unifying hypothesis of type 2 diabetes. Endocr Rev 2002, 23:599-622.
139. Giacco F., Brownlee M. Oxidative stress and diabetic complications. Circ Res 2010, 107:1058-1070.
140. Wu L.L., Chiou C.C., Chang P.Y., Wu J.T. Urinary 8-OHdG: a marker of oxidative stress to DNA and a risk factor for cancer, atherosclerosis and diabetics. Clin Chim Acta 2004, 339:1-9.
141. Shigenaga M.K., Ames B.N. Assays for 8-hydroxy-2'-deoxyguanosine: a biomarker of in vivo oxidative DNA damage. Free Radic Biol Med 1991, 10:211-216.
142. Arif M., Islam M.R., Waise T.M., Hassan F., Mondal S.I., Kabir Y. DNA damage and plasma antioxidant indices in Bangladeshi type 2 diabetic patients. Diabetes Metab 2010, 36:51-57.
143. Tatsch E., Bochi G.V., Piva S.J., et al. Association between DNA strand breakage and oxidative, inflammatory and endothelial biomarkers in type 2 diabetes. Mutat Res 2012, 732:16-20.
144. Vanizor B., Orem A., Karahan S.C., et al. Decreased nitric oxide end-products and its relationship with high density lipoprotein and oxidative stress in people with type 2 diabetes without complications. Diabetes Res Clin Pract 2001, 54:33-39.
145. Dincer Y., Akcay T., Alademir Z., Ilkova H. Assessment of DNA base oxidation and glutathione level in patients with type 2 diabetes. Mutat Res 2002, 505:75-81.
146. Cooke M.S., Lunec J., Evans M.D. Progress in the analysis of urinary oxidative DNA damage. Free Radic Biol Med 2002, 33:1601-1614.
147. Wiseman H., Halliwell B. Damage to DNA by reactive oxygen and nitrogen species: role in inflammatory disease and progression to cancer. Biochem J 1996, 313:17-29.
148. Leinonen J., Lehtimaki T., Toyokuni S., et al. New biomarker evidence of oxidative DNA damage in patients with non-insulin-dependent diabetes mellitus. FEBS Lett 1997, 417:150-152.
149. Kanauchi M., Nishioka H., Hashimoto T. Oxidative DNA damage and tubulointerstitial injury in diabetic nephropathy. Nephron 2002, 91:327-329.
150. Xu G.W., Yao Q.H., Weng Q.F., Su B.L., Zhang X., Xiong J.H. Study of urinary 8-hydroxydeoxyguanosine as a biomarker of oxidative DNA damage in diabetic nephropathy patients. J Pharm Biomed Anal 2004, 36:101-104.
151. Nishikawa T., Sasahara T., Kiritoshi S., et al. Evaluation of urinary 8-hydroxydeoxy-guanosine as a novel biomarker of macrovascular complications in type 2 diabetes. Diabetes Care 2003, 26:1507-1512.
152. Brownlee M., Cerami A., Vlassara H. Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N Engl J Med 1988, 318:1315-1321.
153. Baynes J.W., Thorpe S.R. Role of oxidative stress in diabetic complications: a new perspective on an old paradigm. Diabetes 1999, 48:1-9.
154. Tanji N., Markowitz G.S., Fu C., et al. Expression of advanced glycation end products and their cellular receptor RAGE in diabetic nephropathy and nondiabetic renal disease. J Am Soc Nephrol 2000, 11:1656-1666.
155. Busch M., Franke S., Ruster C., Wolf G. Advanced glycation end-products and the kidney. Eur J Clin Invest 2010, 40:742-755.
156. Makita Z., Radoff S., Rayfield E.J., et al. Advanced glycosylation end products in patients with diabetic nephropathy. N Engl J Med 1991, 325:836-842.
157. Sugiyama S., Miyata T., Ueda Y., et al. Plasma levels of pentosidine in diabetic patients: an advanced glycation end product. J Am Soc Nephrol 1998, 9:1681-1688.
158. Waanders F., Greven W.L., Baynes J.W., et al. Renal accumulation of pentosidine in non-diabetic proteinuria-induced renal damage in rats. Nephrol Dial Transplant 2005, 20:2060-2070.
159. Calabrese V., Mancuso C., Sapienza M., et al. Oxidative stress and cellular stress response in diabetic nephropathy. Cell Stress Chaperones 2007, 12:299-306.
160. Piarulli F., Sartore G., Ceriello A., et al. Relationship between glyco-oxidation, antioxidant status and microalbuminuria in type 2 diabetic patients. Diabetologia 2009, 52:1419-1425.
161. Kerkeni M., Saidi A., Bouzidi H., Letaief A., Ben Yahia S., Hammami M. Pentosidine as a biomarker for microvascular complications in type 2 diabetic patients. Diab Vasc Dis Res 2012, 10.1177/1479164112460253.
162. Tuttle K.R. Linking metabolism and immunology: diabetic nephropathy is an inflammatory disease. J Am Soc Nephrol 2005, 16:1537-1538.
163. Navarro J.F., Mora C., Gomez M., Muros M., Lopez-Aguilar C., Garcia J. Influence of renal involvement on peripheral blood mononuclear cell expression behaviour of tumour necrosis factor-alpha and interleukin-6 in type 2 diabetic patients. Nephrol Dial Transplant 2008, 23:919-926.
164. Elmarakby A.A., Sullivan J.C. Relationship between oxidative stress and inflammatory cytokines in diabetic nephropathy. Cardiovasc Ther 2012, 30:49-59.
165. Wong C.K., Ho A.W., Tong P.C., et al. Aberrant activation profile of cytokines and mitogen-activated protein kinases in type 2 diabetic patients with nephropathy. Clin Exp Immunol 2007, 149:123-131.
166. Galkina E., Ley K. Leukocyte recruitment and vascular injury in diabetic nephropathy. J Am Soc Nephrol 2006, 17:368-377.
167. Lin J., Glynn R.J., Rifai N., et al. Inflammation and progressive nephropathy in type 1 diabetes in the diabetes control and complications trial. Diabetes Care 2008, 31:2338-2343.
168. Marcovecchio M.L., Giannini C., Widmer B., et al. C-reactive protein in relation to the development of microalbuminuria in type 1 diabetes: the Oxford Regional Prospective Study. Diabetes Care 2008, 31:974-976.
169. Bloomgarden Z.T. Inflammation and insulin resistance. Diabetes Care 2003, 26:1922-1926.
170. Dandona P., Aljada A., Bandyopadhyay A. Inflammation: the link between insulin resistance, obesity and diabetes. Trends Immunol 2004, 25:4-7.
171. Ortiz A., Egido J. Is there a role for specific anti-TNF strategies in glomerular diseases?. Nephrol Dial Transplant 1995, 10:309-311.
172. Zhang B., Ramesh G., Norbury C.C., Reeves W.B. Cisplatin-induced nephrotoxicity is mediated by tumor necrosis factor-alpha produced by renal parenchymal cells. Kidney Int 2007, 72:37-44.
173. Navarro J.F., Mora-Fernandez C. The role of TNF-alpha in diabetic nephropathy: pathogenic and therapeutic implications. Cytokine Growth Factor Rev 2006, 17:441-450.
174. Gresser I., Woodrow D., Moss J., Maury C., Tavernier J., Fiers W. Toxic effects of recombinant tumor necrosis factor in suckling mice. Comparisons with interferon alpha/beta. Am J Pathol 1987, 128:13-18.
175. Ortiz A., Lorz C., Gonzalez-Cuadrado S., Garcia del Moral R., O'Valle F., Egido J. Cytokines and Fas regulate apoptosis in murine renal interstitial fibroblasts. J Am Soc Nephrol 1997, 8:1845-1854.
176. Donnahoo K.K., Shames B.D., Harken A.H., Meldrum D.R. Review article: the role of tumor necrosis factor in renal ischemia-reperfusion injury. J Urol 1999, 162:196-203.
177. Misseri R., Meldrum D.R., Dinarello C.A., et al. TNF-alpha mediates obstruction-induced renal tubular cell apoptosis and proapoptotic signaling. Am J Physiol Renal Physiol 2005, 288:F406-F411.
178. Khan S.B., Cook H.T., Bhangal G., Smith J., Tam F.W., Pusey C.D. Antibody blockade of TNF-alpha reduces inflammation and scarring in experimental crescentic glomerulonephritis. Kidney Int 2005, 67:1812-1820.
179. Radeke H.H., Meier B., Topley N., Floge J., Habermehl G.G., Resch K. Interleukin 1-alpha and tumor necrosis factor-alpha induce oxygen radical production in mesangial cells. Kidney Int 1990, 37:767-775.
180. McCarthy E.T., Sharma R., Sharma M., et al. TNF-alpha increases albumin permeability of isolated rat glomeruli through the generation of superoxide. J Am Soc Nephrol 1998, 9:433-438.
181. Bertani T., Abbate M., Zoja C., et al. Tumor necrosis factor induces glomerular damage in the rabbit. Am J Pathol 1989, 134:419-430.
182. Navarro J.F., Mora C., Maca M., Garca J. Inflammatory parameters are independently associated with urinary albumin in type 2 diabetes mellitus. Am J Kidney Dis 2003, 42:53-61.
183. Wu C.C., Chen J.S., Lu K.C., et al. Aberrant cytokines/chemokines production correlate with proteinuria in patients with overt diabetic nephropathy. Clin Chim Acta 2010, 411:700-704.
184. Navarro J.F., Mora C., Muros M., Garcia J. Urinary tumour necrosis factor-alpha excretion independently correlates with clinical markers of glomerular and tubulointerstitial injury in type 2 diabetic patients. Nephrol Dial Transplant 2006, 21:3428-3434.
185. Sekizuka K., Tomino Y., Sei C., et al. Detection of serum IL-6 in patients with diabetic nephropathy. Nephron 1994, 68:284-285.
186. Moriwaki Y., Yamamoto T., Shibutani Y., et al. Elevated levels of interleukin-18 and tumor necrosis factor-alpha in serum of patients with type 2 diabetes mellitus: relationship with diabetic nephropathy. Metabolism 2003, 52:605-608.
187. Pickup J.C., Chusney G.D., Thomas S.M., Burt D. Plasma interleukin-6, tumour necrosis factor alpha and blood cytokine production in type 2 diabetes. Life Sci 2000, 67:291-300.
188. Dalla Vestra M., Mussap M., Gallina P., et al. Acute-phase markers of inflammation and glomerular structure in patients with type 2 diabetes. J Am Soc Nephrol 2005, 16(Suppl. 1):S78-S82.
189. Nosadini R., Velussi M., Brocco E., et al. Course of renal function in type 2 diabetic patients with abnormalities of albumin excretion rate. Diabetes 2000, 49:476-484.
190. Shikano M., Sobajima H., Yoshikawa H., et al. Usefulness of a highly sensitive urinary and serum IL-6 assay in patients with diabetic nephropathy. Nephron 2000, 85:81-85.
191. Viedt C., Dechend R., Fei J., Hansch G.M., Kreuzer J., Orth S.R. MCP-1 induces inflammatory activation of human tubular epithelial cells: involvement of the transcription factors, nuclear factor-kappaB and activating protein-1. J Am Soc Nephrol 2002, 13:1534-1547.
192. Ruiz-Ortega M., Bustos C., Hernandez-Presa M.A., Lorenzo O., Plaza J.J., Egido J. Angiotensin II participates in mononuclear cell recruitment in experimental immune complex nephritis through nuclear factor-kappa B activation and monocyte chemoattractant protein-1 synthesis. J Immunol 1998, 161:430-439.
193. Wada T., Furuichi K., Sakai N., et al. Up-regulation of monocyte chemoattractant protein-1 in tubulointerstitial lesions of human diabetic nephropathy. Kidney Int 2000, 58:1492-1499.
194. Giunti S., Tesch G.H., Pinach S., et al. Monocyte chemoattractant protein-1 has prosclerotic effects both in a mouse model of experimental diabetes and in vitro in human mesangial cells. Diabetologia 2008, 51:198-207.
195. Kato S., Luyckx V.A., Ots M., et al. Renin-angiotensin blockade lowers MCP-1 expression in diabetic rats. Kidney Int 1999, 56:1037-1048.
196. Ruster C., Wolf G. The role of chemokines and chemokine receptors in diabetic nephropathy. Front Biosci 2008, 13:944-955.
197. Tashiro K., Koyanagi I., Saitoh A., et al. Urinary levels of monocyte chemoattractant protein-1 (MCP-1) and interleukin-8 (IL-8), and renal injuries in patients with type 2 diabetic nephropathy. J Clin Lab Anal 2002, 16:1-4.
198. Banba N., Nakamura T., Matsumura M., Kuroda H., Hattori Y., Kasai K. Possible relationship of monocyte chemoattractant protein-1 with diabetic nephropathy. Kidney Int 2000, 58:684-690.
199. Zheng M., Ye S., Zhai Z., et al. Rosiglitazone protects diabetic rats against kidney disease through the suppression of renal monocyte chemoattractant protein-1 expression. J Diabetes Complications 2009, 23:124-129.
200. Morii T., Fujita H., Narita T., et al. Association of monocyte chemoattractant protein-1 with renal tubular damage in diabetic nephropathy. J Diabetes Complications 2003, 17:11-15.
201. Ibrahim S., Rashed L. Correlation of urinary monocyte chemo-attractant protein-1 with other parameters of renal injury in type-II diabetes mellitus. Saudi J Kidney Dis Transpl 2008, 19:911-917.
202. Morii T., Fujita H., Narita T., et al. Increased urinary excretion of monocyte chemoattractant protein-1 in proteinuric renal diseases. Ren Fail 2003, 25:439-444.
203. Dechanet J., Grosset C., Taupin J.L., et al. CD40 ligand stimulates proinflammatory cytokine production by human endothelial cells. J Immunol 1997, 159:5640-5647.
204. Antoniades C., Bakogiannis C., Tousoulis D., Antonopoulos A.S., Stefanadis C. The CD40/CD40 ligand system: linking inflammation with atherothrombosis. J Am Coll Cardiol 2009, 54:669-677.
205. Anand S.X., Viles-Gonzalez J.F., Badimon J.J., Cavusoglu E., Marmur J.D. Membrane-associated CD40L and sCD40L in atherothrombotic disease. Thromb Haemost 2003, 90:377-384.
206. Henn V., Slupsky J.R., Grafe M., et al. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature 1998, 391:591-594.
207. van Kooten C., Gerritsma J.S., Paape M.E., van Es L.A., Banchereau J., Daha M.R. Possible role for CD40-CD40L in the regulation of interstitial infiltration in the kidney. Kidney Int 1997, 51:711-721.
208. Varo N., Vicent D., Libby P., et al. Elevated plasma levels of the atherogenic mediator soluble CD40 ligand in diabetic patients: a novel target of thiazolidinediones. Circulation 2003, 107:2664-2669.
209. Marx N., Imhof A., Froehlich J., et al. Effect of rosiglitazone treatment on soluble CD40L in patients with type 2 diabetes and coronary artery disease. Circulation 2003, 107:1954-1957.
210. Cipollone F., Chiarelli F., Davi G., et al. Enhanced soluble CD40 ligand contributes to endothelial cell dysfunction in vitro and monocyte activation in patients with diabetes mellitus: effect of improved metabolic control. Diabetologia 2005, 48:1216-1224.
211. Chiarelli F., Giannini C., Verrotti A., Mezzetti A., Mohn A. Increased concentrations of soluble CD40 ligand may help to identify type 1 diabetic adolescents and young adults at risk for developing persistent microalbuminuria. Diabetes Metab Res Rev 2008, 24:570-576.
212. Neubauer H., Setiadi P., Gunesdogan B., Pinto A., Borgel J., Mugge A. Influence of glycaemic control on platelet bound CD40-CD40L system, P-selectin and soluble CD40 ligand in type 2 diabetes. Diabet Med 2010, 27:384-390.
213. Ben Ameur R., Molina L., Bolvin C., et al. Proteomic approaches for discovering biomarkers of diabetic nephropathy. Nephrol Dial Transplant 2010, 25:2866-2875.
214. El-Asrar M.A., Adly A.A., Ismail E.A. Soluble CD40L in children and adolescents with type 1 diabetes: relation to microvascular complications and glycemic control. Pediatr Diabetes 2012, 13:616-624.
215. Chiarelli F., Cipollone F., Romano F., et al. Increased circulating nitric oxide in young patients with type 1 diabetes and persistent microalbuminuria: relation to glomerular hyperfiltration. Diabetes 2000, 49:1258-1263.
216. Prabhakar S.S. Pathogenic role of nitric oxide alterations in diabetic nephropathy. Curr Diab Rep 2005, 5:449-454.
217. Awad A.S., Webb R.L., Carey R.M., Siragy H.M. Renal nitric oxide production is decreased in diabetic rats and improved by AT1 receptor blockade. J Hypertens 2004, 22:1571-1577.
218. Goligorsky M.S., Chen J., Brodsky S. Workshop: endothelial cell dysfunction leading to diabetic nephropathy: focus on nitric oxide. Hypertension 2001, 37:744-748.
219. Sarafidis P.A., Ruilope L.M. Insulin resistance, hyperinsulinemia, and renal injury: mechanisms and implications. Am J Nephrol 2006, 26:232-244.
220. Chin-Dusting J.P., Willems L., Kaye D.M. l-arginine transporters in cardiovascular disease: a novel therapeutic target. Pharmacol Ther 2007, 116:428-436.
221. Mumtaz F.H., Dashwood M.R., Khan M.A., Thompson C.S., Mikhailidis D.P., Morgan R.J. Down-regulation of nitric oxide synthase in the diabetic rabbit kidney: potential relevance to the early pathogenesis of diabetic nephropathy. Curr Med Res Opin 2004, 20:1-6.
222. Prabhakar S., Starnes J., Shi S., Lonis B., Tran R. Diabetic nephropathy is associated with oxidative stress and decreased renal nitric oxide production. J Am Soc Nephrol 2007, 18:2945-2952.
223. Erdely A., Freshour G., Maddox D.A., Olson J.L., Samsell L., Baylis C. Renal disease in rats with type 2 diabetes is associated with decreased renal nitric oxide production. Diabetologia 2004, 47:1672-1676.
224. Koo J.R., Vaziri N.D. Effects of diabetes, insulin and antioxidants on NO synthase abundance and NO interaction with reactive oxygen species. Kidney Int 2003, 63:195-201.
225. Apakkan Aksun S., Ozmen B., Ozmen D., et al. Serum and urinary nitric oxide in type 2 diabetes with or without microalbuminuria: relation to glomerular hyperfiltration. J Diabetes Complications 2003, 17:343-348.
226. Vedel P., Obel J., Nielsen F.S., et al. Glomerular hyperfiltration in microalbuminuric NIDDM patients. Diabetologia 1996, 39:1584-1589.
227. Maejima K., Nakano S., Himeno M., et al. Increased basal levels of plasma nitric oxide in type 2 diabetic subjects. Relationship to microvascular complications. J Diabetes Complications 2001, 15:135-143.
228. Merchant M.L., Klein J.B. Proteomic discovery of diabetic nephropathy biomarkers. Adv Chronic Kidney Dis 2010, 17:480-486.
229. Jungblut P., Wittmann-Liebold B. Protein analysis on a genomic scale. J Biotechnol 1995, 41:111-120.
230. Thongboonkerd V. Study of diabetic nephropathy in the proteomic era. Contrib Nephrol 2011, 170:172-183.
231. Cutillas P.R., Biber J., Marks J., et al. Proteomic analysis of plasma membrane vesicles isolated from the rat renal cortex. Proteomics 2005, 5:101-112.
232. Magni F., Sarto C., Valsecchi C., et al. Expanding the proteome two-dimensional gel electrophoresis reference map of human renal cortex by peptide mass fingerprinting. Proteomics 2005, 5:816-825.
233. Yoshida Y., Miyazaki K., Kamiie J., et al. Two-dimensional electrophoretic profiling of normal human kidney glomerulus proteome and construction of an extensible markup language (XML)-based database. Proteomics 2005, 5:1083-1096.
234. Barile M., Pisitkun T., Yu M.J., et al. Large scale protein identification in intracellular aquaporin-2 vesicles from renal inner medullary collecting duct. Mol Cell Proteomics 2005, 4:1095-1106.
235. Dihazi H., Asif A.R., Agarwal N.K., Doncheva Y., Muller G.A. Proteomic analysis of cellular response to osmotic stress in thick ascending limb of Henle's loop (TALH) cells. Mol Cell Proteomics 2005, 4:1445-1458.
236. Starkey J.M., Tilton R.G. Proteomics and systems biology for understanding diabetic nephropathy. J Cardiovasc Transl Res 2012, 5:479-490.
237. Rossing K., Mischak H., Dakna M., et al. Urinary proteomics in diabetes and CKD. J Am Soc Nephrol 2008, 19:1283-1290.
238. Merchant M.L., Perkins B.A., Boratyn G.M., et al. Urinary peptidome may predict renal function decline in type 1 diabetes and microalbuminuria. J Am Soc Nephrol 2009, 20:2065-2074.
239. Wolkow P.P., Niewczas M.A., Perkins B., et al. Association of urinary inflammatory markers and renal decline in microalbuminuric type 1 diabetics. J Am Soc Nephrol 2008, 19:789-797.
240. Mischak H., Kaiser T., Walden M., et al. Proteomic analysis for the assessment of diabetic renal damage in humans. Clin Sci 2004, 107:485-495.
241. Kim H.J., Cho E.H., Yoo J.H., et al. Proteome analysis of serum from type 2 diabetics with nephropathy. J Proteome Res 2007, 6:735-743.
242. Zurbig P., Jerums G., Hovind P., et al. Urinary proteomics for early diagnosis in diabetic nephropathy. Diabetes 2012, 61:3304-3313.
243. Alkhalaf A., Zurbig P., Bakker S.J., et al. Multicentric validation of proteomic biomarkers in urine specific for diabetic nephropathy. PLoS One 2010, 5:e13421.
244. Papale M., Di Paolo S., Magistroni R., et al. Urine proteome analysis may allow noninvasive differential diagnosis of diabetic nephropathy. Diabetes Care 2010, 33:2409-2415.
245. Overgaard A.J., Hansen H.G., Lajer M., et al. Plasma proteome analysis of patients with type 1 diabetes with diabetic nephropathy. Proteome Sci 2010, 8:4.
246. Roscioni S.S., de Zeeuw D., Hellemons M.E., et al. A urinary peptide biomarker set predicts worsening of albuminuria in type 2 diabetes mellitus. Diabetologia 2013, 56:259-267.
247. Fliser D., Novak J., Thongboonkerd V., et al. Advances in urinary proteome analysis and biomarker discovery. J Am Soc Nephrol 2007, 18:1057-1071.
248. Rao P.V., Lu X., Standley M., et al. Proteomic identification of urinary biomarkers of diabetic nephropathy. Diabetes Care 2007, 30:629-637.
249. Good D.M., Zurbig P., Argiles A., et al. Naturally occurring human urinary peptides for use in diagnosis of chronic kidney disease. Mol Cell Proteomics 2010, 9:2424-2437.
250. Mogensen C.E., Neldam S., Tikkanen I., et al. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. BMJ 2000, 321:1440-1444.
251. Waikar S.S., Bonventre J.V. Biomarkers for the diagnosis of acute kidney injury. Curr Opin Nephrol Hypertens 2007, 16:557-564.
252. Hinokio Y., Suzuki S., Hirai M., Suzuki C., Suzuki M., Toyota T. Urinary excretion of 8-oxo-7, 8-dihydro-2'-deoxyguanosine as a predictor of the development of diabetic nephropathy. Diabetologia 2002, 45:877-882.
253. Nin J.W., Jorsal A., Ferreira I., et al. Higher plasma levels of advanced glycation end products are associated with incident cardiovascular disease and all-cause mortality in type 1 diabetes: a 12-year follow-up study. Diabetes Care 2011, 34:442-447.
254. Niewczas M.A., Ficociello L.H., Johnson A.C., et al. Serum concentrations of markers of TNFalpha and Fas-mediated pathways and renal function in nonproteinuric patients with type 1 diabetes. Clin J Am Soc Nephrol 2009, 4:62-70.
255. El Mesallamy H.O., Ahmed H.H., Bassyouni A.A., Ahmed A.S. Clinical significance of inflammatory and fibrogenic cytokines in diabetic nephropathy. Clin Biochem 2012, 45:646-650.
256. Horoz O.O., Yuksel B., Bayazit A.K., et al. Ambulatory blood pressure monitoring and serum nitric oxide concentration in type 1 diabetic children. Endocr J 2009, 56:477-485.